P. Rowe

发表

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, T. Park-Simon, 2021, The Lancet. Oncology.

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

J. Ledermann, J. Barrett, D. Hodgson, 2021, British Journal of Cancer.

gastrointestinal tumours, non-colorectalOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study

Y. Bang, D. Hodgson, S. Im, 2016 .

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Jing Wang, I. Wistuba, W. Lu, 2015, Clinical Cancer Research.

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

S. Park, Y. Bang, D. Hodgson, 2017, The Lancet. Oncology.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

D. Matei, J. Ledermann, C. Scott, 2016, The Lancet. Oncology.

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial

K. Yonemori, I. Ray-Coquard, Takashi Matsumoto, 2021, Journal of gynecologic oncology.

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

D. Berton, I. Vergote, S. Pignata, 2021, Gynecologic Oncology.

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

D. Matei, J. Ledermann, C. Scott, 2018, British Journal of Cancer.

Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

J. Ledermann, C. Scott, M. Friedlander, 2017 .

392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

M. Friedlander, N. Colombo, G. Scambia, 2020 .

Analysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score

J. Barrett, D. Hodgson, T. French, 2019, Annals of Oncology.